Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2008
At a glance
- Drugs Capecitabine; WX UK1
- Indications Solid tumours
- Focus Adverse reactions
- 25 Jan 2008 Status changed from recruiting to completed; reported by Wilex in a media release.
- 26 Aug 2005 New trial record.